New frontiers in the medical management of gastrointestinal stromal tumours

The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ther Adv Med Oncol
Main Authors: Mazzocca, Alessandro, Napolitano, Andrea, Silletta, Marianna, Spalato Ceruso, Mariella, Santini, Daniele, Tonini, Giuseppe, Vincenzi, Bruno
格式: Artigo
語言:Inglês
出版: SAGE Publications 2019
主題:
Review
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535752/
https://ncbi.nlm.nih.gov/pubmed/31205499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919841946
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍